ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0674

Quantitative Imaging in Systemic Sclerosis Patients Receiving Sodium Thiosulfate for Calcinosis Cutis

Ian Odell1, Crystal Cheung1, Megan Wu2, Stephanie Perez3, Agrani Dixit4, Cassandra van Horn3, Muhammad Hamdan5, Baran Gunes6, Sophia Kujawski7, Hyojeong Lee3, Annie Wang3, Denise Esserman8, Michael Zamani9, F. Perry Wilson3, John Onofrey3, Xenophon Papademetris3 and Monique Hinchcliff10, 1Yale University School of Medicine, New Haven, CT, 2Yale University School of Medicine, Greenville, 3Yale University School of Medicine, New Haven, 4Yale School of Medicine, New Haven, CT, 5Yale University School of Medicine, Mansfield, 6Yale University School of Medicine, Pompton Plains, NJ, 7The George Washington University, New Haven, CT, 8Yale University School of Public Health, New Haven, 9Independent Statistician, Washington D.C., 10Yale School of Medicine, Westport, CT

Meeting: ACR Convergence 2025

Keywords: calcinosis, Computed tomography (CT), Cutaneous, Scleroderma, Systemic, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0671–0710) Systemic Sclerosis & Related Disorders – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Calcinosis cutis (CC) is a disabling skin condition associated with systemic sclerosis (SSc). Although many CC treatments including sodium thiosulfate (STS) have been proposed, no clinical trials have been conducted due, in part, to a lack of validated quantitative outcome measures.

Methods: Patients with severe SSc-CC, enrolled in an open-label case series were treated with 25% STS was administered topically twice daily for 6-12 months or injected intradermally monthly for six months (0.1ml per injection for total of 1-2.5ml STS injected per session) to a patient-selected region-of-interest (ROI). All patients satisfied the ACR classification criteria of SSc. Three clinical coordinators independently assessed computer-assisted annotation of SSc-CC on computed tomography (CT) exams for quantitative measurement of volume changes compared to symptomatic and photographic responses during STS treatment using BioImage Suite Web software. Inter-rater agreement and test-retest reliability were determined with intraclass coefficient (ICC).

Results: Five women, with SSc-CC involving the upper arm, bilateral ischial tuberosities, hands (two patients) and bilateral patellae, received topical (n=2) or intralesional (n=3) STS. Variable changes in symptoms, digital camera imaging, and CC volume by CT imaging (28% reduction in upper arm; 75% and 10% reductions in left and right, buttock, respectively; 18% increase in left forefinger; 27% increase in right hand; and 12% reduction in left, and 4% increase in right, patellae) were observed. Inter-rater agreement was excellent with an ICC of 0.93. Volume of CC on repeated measures performed one week apart was within 3%. Annotation time ranged from < 30 minutes for arm and buttock to >four hours per case for other ROI.

Conclusion: Intradermal STS treatment was associated with symptomatic and volumetric improvement in arm and buttocks, but not finger CC. Topical STS was not associated with symptomatic or imaging CC improvement in fingers or patellae. Computer-assisted annotation and volumetric measurement of CC on CT imaging appears to be a reproducible and sensitive quantitative outcome. However, time to annotate CC close to bone was lengthy due to similar radiographic density. Computer-assisted quantification of CC on CT is a useful quantitative outcome for future clinical trials, but additional methods for automating CC annotation need to be developed.

Supporting image 1Figure 1. Intralesional sodium thiosulfate treatment of arm calcinosis cutis (CC) (Case 1) and buttock CC (Case 2). (A, B) Pre- and post-STS treatment photographs of left upper arm, respectively. (C, D) Rasterized pre- and post-STS treatment computed tomography (CT) images of CC lesions, respectively, with CC painted red. (E). Pre- and post-STS treatment CC lesional volume quantification. Post-STS treatment CT exams 1 and 2 were repeated one week apart, VOI=volume of interest. (F) Average pre- and post-treatment CC lesional radio density quantification among 3 raters. (G, I) Left and right buttock photographs of pre- and post-STS treatment, respectively. (H, J) Pre- STS treatment axial CT images without and with painting of CC lesions. (K) Pre- and post-treatment CC lesional volume quantification, VOI=volume of interest. (L) Average pre- and post-treatment CC lesional radio density quantification among 3 raters. (M) Post-treatment axial CT image without painting of CC lesions.

Supporting image 2Figure 2. Intralesional (Case 3) and topical (Case 4) sodium thiosulfate treatment of finger calcinosis cutis (CC). (A, B) Pre- and post-STS treatment photographs of the right index finger, respectively. (C) Pre-STS treatment axial CT images without and with painting of CC lesions. (D) Post-treatment axial CT images without and with painting of CC lesions. (E) Average pre- and post-treatment CC lesional volume quantification among 3 raters, VOI=volume of interest. (F) Average pre- and post-treatment CC lesional radio density quantification among 3 raters. (G) Average pre- and post-treatment CC lesional SCTC scores among 3 raters. (H) Pre-STS treatment axial CT images without and with painting of CC lesions. (I) Post-treatment axial CT images without and with painting of CC lesions. (J) Average pre- and post-treatment CC lesional volume quantification among 3 raters, VOI=volume of interest. (K) Average pre- and post-treatment CC lesional radio density quantification among 3 raters. (L) Average pre- and post-treatment CC lesional SCTC scores among 3 raters.

Supporting image 3Figure 3. Topical sodium thiosulfate treatment of knee calcinosis cutis (CC). (A, B) Left and right patellae photographs of pre- and post-STS treatment, respectively. (C) Pre- STS treatment axial CT images without painting of CC lesions. (D) Post- STS treatment axial CT images of right patella without painting of CC lesions. (E) Average pre- and post-treatment CC lesional volume quantification among 3 raters, VOI=volume of interest. (F) Average pre- and post-treatment CC lesional radio density quantification among 3 raters. (G) Pre-STS treatment axial CT image with painting of CC lesion.


Disclosures: I. Odell: Plythera, Inc, 10, Ventus Therapeutics, 5; C. Cheung: None; M. Wu: None; S. Perez: None; A. Dixit: None; C. van Horn: None; M. Hamdan: None; B. Gunes: None; S. Kujawski: None; H. Lee: None; A. Wang: None; D. Esserman: Ablative Solutions, 1, Conformal, 1, EMBLOK, 1, PhaseBio, 1, REVA Medical, 1; M. Zamani: None; F. Wilson: Amgen, 5; J. Onofrey: None; X. Papademetris: None; M. Hinchcliff: AbbVie/Abbott, Boehringer Ingelheim, Kadmon,, 2, 5.

To cite this abstract in AMA style:

Odell I, Cheung C, Wu M, Perez S, Dixit A, van Horn C, Hamdan M, Gunes B, Kujawski S, Lee H, Wang A, Esserman D, Zamani M, Wilson F, Onofrey J, Papademetris X, Hinchcliff M. Quantitative Imaging in Systemic Sclerosis Patients Receiving Sodium Thiosulfate for Calcinosis Cutis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/quantitative-imaging-in-systemic-sclerosis-patients-receiving-sodium-thiosulfate-for-calcinosis-cutis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/quantitative-imaging-in-systemic-sclerosis-patients-receiving-sodium-thiosulfate-for-calcinosis-cutis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology